MedTrace Logo

Antiplatelet Effect of Ginkgo Diterpene Lactone Meglumine Injection in Acute Ischemic Stroke

NCT05531942 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2023-07-14

No results posted yet for this study

Summary

This study evaluates the addition of Ginkgo Diterpene Lactone Meglumine Injection to aspirin in the treatment of acute ischemic stroke.Half of patient will receive Ginkgo Diterpene Lactone Meglumine Injection(25mg once/day D1-D14) and aspirin(100mg once/day D1-D14) in combination, while the other half will receive aspirin(100mg once/day D1-D14).

Conditions

Interventions

DRUG

Ginkgo Diterpene Lactone Meglumine Injection

The injection was diluted with 250ml physiological saline,intravenous drip for about 3 hours.

DRUG

Acetylsalicylic acid

Acetylsalicylic acid (Aspirin) given at a dose of 100 mg/d for 90 days.

Sponsors & Collaborators

  • Shanghai Yueyang Integrated Medicine Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2023-10-01
Completion
2023-11-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05531942 on ClinicalTrials.gov